QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-bolt-biotherapeutics

HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Neutral.

 bolt-biotherapeutics-q2-eps-056-misses-048-estimate-sales-127m-beat-89150k-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate o...

 leerink-partners-downgrades-bolt-biotherapeutics-to-market-perform-lowers-price-target-to-1

Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Outperform to Market Perform and...

 jones-trading-downgrades-bolt-biotherapeutics-to-hold

Jones Trading analyst Soumit Roy downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Hold.

 hc-wainwright--co-downgrades-bolt-biotherapeutics-to-neutral

HC Wainwright & Co. analyst Edward White downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Neutral.

 guggenheim-downgrades-bolt-biotherapeutics-to-neutral

Guggenheim analyst Michael Schmidt downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Neutral.

 stifel-downgrades-bolt-biotherapeutics-to-hold-lowers-price-target-to-15

Stifel analyst Stephen Willey downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Hold and lowers the price target fro...

 bolt-biotherapeutics-q1-2024-gaap-eps-028-beats-049-estimate-sales-530m-beat-206m-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-maintains-buy-on-bolt-biotherapeutics-maintains-8-price-target

HC Wainwright & Co. analyst Edward White maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price ...

 bolt-biotherapeutics-q4-eps-047-beats-048-estimate-sales-209m-beat-171m-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...

 bolt-biotherapeutics-enrolls-first-patient-in-phase-2-clinical-study-evaluating-bdc-1001-in-patients-with-her2-positive-breast-cancer-previously-treated-with-enhertu

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the t...

 bolt-biotherapeutics-q3-eps-043-beats-050-estimate-sales-253m-beat-172m-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of ...

 bolt-biotherapeutics-presents-updated-clinical-data-from-phase-1-dose-escalation-trial-of-bdc-1001-as-monotherapy-and-in-combination-with-nivolumab-in-her2-expressing-tumors-at-esmo-2023-congress

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) Improved efficacy with one pa...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION